Vaccines Market to grow at 9% CAGR from 2017 to 2024 - PowerPoint PPT Presentation

View by Category
About This Presentation

Vaccines Market to grow at 9% CAGR from 2017 to 2024


Get more details @ Some of the major players in vaccines market are AstraZeneca, Abbott, Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, Sanofi Pasteur, Pfizer, GlaxoSmithKline, Emergent BioSolutions, Novartis, Astellas Pharma, CSL and Novavax. – PowerPoint PPT presentation

Number of Views:25


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Vaccines Market to grow at 9% CAGR from 2017 to 2024

Global Vaccines Market to hit 65 Bn by 2024
Global Market Insights Inc.
Key Insights from Vaccines Market
  • The global vaccines market has recently witnessed
    one of its key participants, Novartis NVS
    announcing its decision to acquire the France
    based radiopharmaceutical company, Advanced
    Accelerator Applications (AAAP).
  • Global Market Insights, Inc. says, in 2016,
    vaccines market size stood at a revenue of USD 32
  • This purchase apparently, is expected to
    strengthen Novartis product portfolio in the
    cancer vertical, by adding AAAPs RadioLigand
  • Currently, it has been observed most of the
    pharmaceutical giants have been striving to come
    up with innovative vaccination products for
    influenza, which seems to be raging across the
    globe in seasonal intervals.
  • The company also plans to recruit more workforce
    to increase the production rate, so that the
    vaccines can be shipped in readiness in case of a
  • Seqiruss investment is likely to encourage
    regional vaccines industry players to follow
    suit, which would subsequently help stimulate UK
    vaccines market trends over the coming years.

  • Regulatory organizations have been making
    continuous efforts to generate awareness among
    the global populace regarding the advantages of
  • For instance, the U.S. Centers for Disease
    Control and Prevention (CDC) has inked guidelines
    to encourage people to take seasonal influenza
    vaccines for controlling and preventing the virus
    from spreading, especially in young children, the
    elderly, and pregnant women.
  • As per estimates, U.S. covered a major share of
    the regional vaccines market revenue in 2016,
    pertaining to the numerous efforts undertaken by
    regulatory bodies.
  • Considering the myriad advantages that vaccines
    provide to improve an individuals immunity
    system, researchers have been striving to conduct
    eminent study programs involving the methodology
    of combining vaccines with other cancer treatment
    methods such as radiations, chemotherapy, and
    Herceptin to enhance patient survival rate.
  • Notable behemoths across the vaccines market,
    namely, Merck Co., AstraZeneca, Pfizer,
    Novartis, Bristol-Myers Squibb, CSL, Johnson
    Johnson, Abbott, GlaxoSmithKline, Astellas
    Pharma, Sanofi Pasteur, Novavax, and Emergent

U.S. Vaccines Market, By Age Group, 2013 - 2024
(USD Billion)

Table of Content
Chapter 1. Methodology 1.1. Methodology
1.1.1. Initial data
exploration 1.1.2. Statistical modeling and
forecast 1.1.3. Industry insights and
validation 1.1.4. Market definition and
forecast assumptions 1.2. Data
sources 1.2.1. Primary 1.2.2.
Secondary Chapter 2. Executive Summary 2.1.
Global Vaccines industry 3600 synopsis, 2013 -
2024 2.1.1. Business trends 2.1.2. Age group
trends 2.1.3. Disease trends 2.1.4.
Technology trends 2.1.5. Regional trends
Table of Content
Chapter 3. Vaccines Industry Insights 3.1.
Industry segmentation 3.2. Industry landscape,
2013 2024 3.3. Industry impact forces 3.3.1.
Growth drivers government
funding for vaccine development
Increasing vaccines RD in developed
nations Increasing disease prevalence
in underdeveloped countries Growing
incidences of cancer HIV in Asia
Pacific 3.3.2. Industry pitfalls
challenges High cost of vaccine
storage and transportation Stringent
regulations for the approval of vaccines in
developed nations 3.4. Growth potential
analysis 3.4.1. By age group 3.4.2. By
technology 3.4.3. By disease
Table of Content
3.5. Regulatory landscape 3.5.1. U.S 3.5.2.
Europe 3.5.3. Asia Pacific 3.6. Reimbursement
scenario 3.6.1. U.S 3.6.2. Europe 3.7.
Technology landscape 3.8. Pricing analysis 3.9.
Pipeline product analysis 3.9.1.
Malaria 3.9.2. HIV 3.9.3. Zika 3.9.4.
Ebola 3.10. Porters analysis 3.11. Company
market share analysis, 2016 3.11.1. Strategy
dashboard 3.12. PESTEL analysis

Browse Full Market Research Report On Vaccines
Market _at_ http// Request for a
Sample of this Research Report _at_ https//www.gmins
Stay In Touch Website Soci
al Media